A detailed history of Barclays PLC transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 273,085 shares of AKBA stock, worth $502,476. This represents 0.0% of its overall portfolio holdings.

Number of Shares
273,085
Previous 273,085 -0.0%
Holding current value
$502,476
Previous $360,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$0.94 - $1.55 $188,453 - $310,747
200,482 Added 276.13%
273,085 $360,000
Q2 2024

Aug 14, 2024

SELL
$0.86 - $1.63 $118,161 - $223,957
-137,397 Reduced 65.43%
72,603 $74,000
Q1 2024

May 15, 2024

BUY
$1.27 - $2.24 $266,700 - $470,400
210,000 New
210,000 $384,000
Q2 2022

Aug 12, 2022

SELL
$0.32 - $0.67 $26,926 - $56,377
-84,146 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$0.72 - $2.93 $144,449 - $587,828
-200,624 Reduced 70.45%
84,146 $61,000
Q4 2021

Feb 14, 2022

BUY
$2.26 - $3.34 $217,893 - $322,019
96,413 Added 51.19%
284,770 $643,000
Q3 2021

Nov 09, 2021

BUY
$2.35 - $3.88 $44,840 - $74,034
19,081 Added 11.27%
188,357 $542,000
Q2 2021

Aug 13, 2021

SELL
$2.83 - $4.2 $192,275 - $285,356
-67,942 Reduced 28.64%
169,276 $642,000
Q1 2021

May 13, 2021

BUY
$2.92 - $5.06 $214,403 - $371,535
73,426 Added 44.83%
237,218 $804,000
Q4 2020

Feb 11, 2021

SELL
$2.22 - $3.78 $45,956 - $78,249
-20,701 Reduced 11.22%
163,792 $458,000
Q3 2020

Nov 12, 2020

BUY
$2.39 - $13.08 $118,159 - $646,662
49,439 Added 36.61%
184,493 $463,000
Q2 2020

Aug 12, 2020

BUY
$6.67 - $13.58 $8,650 - $17,613
1,297 Added 0.97%
135,054 $1.83 Million
Q1 2020

May 13, 2020

SELL
$4.1 - $10.24 $152,245 - $380,241
-37,133 Reduced 21.73%
133,757 $1.01 Million
Q4 2019

Feb 10, 2020

BUY
$3.16 - $6.73 $164,010 - $349,300
51,902 Added 43.62%
170,890 $1.08 Million
Q3 2019

Nov 14, 2019

SELL
$3.55 - $5.4 $37,683 - $57,321
-10,615 Reduced 8.19%
118,988 $467,000
Q2 2019

Aug 14, 2019

BUY
$4.1 - $8.05 $85,739 - $168,341
20,912 Added 19.24%
129,603 $628,000
Q1 2019

May 15, 2019

BUY
$5.41 - $8.73 $576,992 - $931,080
106,653 Added 5233.22%
108,691 $891,000
Q4 2018

Feb 14, 2019

SELL
$5.39 - $9.15 $501,307 - $851,014
-93,007 Reduced 97.86%
2,038 $11,000
Q3 2018

Nov 14, 2018

BUY
$7.44 - $10.65 $596,985 - $854,556
80,240 Added 541.98%
95,045 $839,000
Q2 2018

Aug 14, 2018

SELL
$9.15 - $11.34 $149,511 - $185,295
-16,340 Reduced 52.46%
14,805 $148,000
Q1 2018

May 15, 2018

BUY
$9.53 - $15.68 $125,424 - $206,364
13,161 Added 73.18%
31,145 $296,000
Q4 2017

Feb 14, 2018

BUY
$14.24 - $19.59 $233,763 - $321,589
16,416 Added 1046.94%
17,984 $268,000
Q3 2017

Nov 14, 2017

BUY
$13.06 - $19.67 $20,478 - $30,842
1,568
1,568 $30,000

Others Institutions Holding AKBA

About Akebia Therapeutics, Inc.


  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $338M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.